The operation represents a further strategic step in the process initiated with the establishment of ROELMI BIOTECH in 2024, aimed at developing and enhancing new solutions and ingredients obtained through approaches and technologies based on precision fermentation methods. The partnership will enable ROELMI HPC and YSBIOTECH to support research and development of new technologies, develop proprietary platforms, foster internationalisation as well as the consolidation of scientific and technological expertise by transforming innovation into new solutions for industry.
The entry of ROELMI HPC opens up new perspectives for industrial collaboration and development, leveraging the complementarity of expertise and the sharing of an innovation-oriented vision.
A distinctive element of the project is YSBIOTECH 's research and development laboratory; 5000sqm based on cutting-edge expertise and technologies in genetics and biotechnology and a dedicated staff of +60 collaborators with STEM (Science, Technology, Engineering, and Mathematics) profiles. The laboratory is a strategic asset for research activities, providing scientific know-how and infrastructure dedicated to the study and development of new solutions applicable to the formulation of ingredients for the cosmetics and food sectors. Among the various awards, YSBIOTECH has 66 patent applications of which 34 patents have been granted.
The operation confirms the desire to build a platform dedicated to the development of innovative ingredients: active ingredients derived from biotech (precision fermentation) and biomolecular, proteins and extracts starting from the available scientific and biotechnological expertise and orienting them towards concrete applications in the cosmetics and nutraceutical market
The entry into the capital of YSBIOTECH represents an opportunity to develop new synergies and enhance complementary skills. We believe in the potential of biotechnological innovation and the possibility of transforming research into concrete solutions, capable of responding to market developments. This operation is part of our vision of growth, based on scientific expertise, innovation and industrial development.
- Declares Rosella Malanchin, CEO of ROELMI HPC.
ROELMI HPC's entry into our capital represents an important step in YSBIOTECH's development journey in the cosmetics market. Collaboration will allow us to look at new opportunities, build on our wealth of expertise, and strengthen the foundation for future growth. We share a vision oriented towards innovation and the construction of projects capable of generating value in the long term.
- Declares Mr Yu, CEO of YSBIOTECH.